MRK vs. BMY
Compare and contrast key facts about Merck & Co., Inc. (MRK) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: MRK or BMY.
Correlation
The correlation between MRK and BMY is 0.50, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
MRK vs. BMY - Performance Comparison
Loading data...
Key characteristics
MRK:
-1.46
BMY:
0.36
MRK:
-1.97
BMY:
0.70
MRK:
0.74
BMY:
1.08
MRK:
-0.90
BMY:
0.20
MRK:
-1.67
BMY:
1.13
MRK:
23.41%
BMY:
8.62%
MRK:
27.67%
BMY:
31.53%
MRK:
-68.62%
BMY:
-70.62%
MRK:
-41.45%
BMY:
-35.93%
Fundamentals
MRK:
$187.83B
BMY:
$95.14B
MRK:
$7.00
BMY:
$2.73
MRK:
10.69
BMY:
17.12
MRK:
0.69
BMY:
2.26
MRK:
2.94
BMY:
2.00
MRK:
3.89
BMY:
5.36
MRK:
$63.92B
BMY:
$47.64B
MRK:
$51.75B
BMY:
$31.43B
MRK:
$27.30B
BMY:
$16.18B
Returns By Period
In the year-to-date period, MRK achieves a -22.88% return, which is significantly lower than BMY's -15.53% return. Over the past 10 years, MRK has outperformed BMY with an annualized return of 6.00%, while BMY has yielded a comparatively lower -0.58% annualized return.
MRK
-22.88%
-0.52%
-19.71%
-40.16%
3.11%
6.00%
BMY
-15.53%
-5.29%
-15.02%
11.19%
-2.62%
-0.58%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
MRK vs. BMY — Risk-Adjusted Performance Rank
MRK
BMY
MRK vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Merck & Co., Inc. (MRK) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
MRK vs. BMY - Dividend Comparison
MRK's dividend yield for the trailing twelve months is around 4.15%, less than BMY's 5.22% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRK Merck & Co., Inc. | 4.15% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% | 3.12% |
BMY Bristol-Myers Squibb Company | 5.22% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
MRK vs. BMY - Drawdown Comparison
The maximum MRK drawdown since its inception was -68.62%, roughly equal to the maximum BMY drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for MRK and BMY. For additional features, visit the drawdowns tool.
Loading data...
Volatility
MRK vs. BMY - Volatility Comparison
Merck & Co., Inc. (MRK) and Bristol-Myers Squibb Company (BMY) have volatilities of 12.13% and 11.57%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
MRK vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Merck & Co., Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
MRK vs. BMY - Profitability Comparison
MRK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Merck & Co., Inc. reported a gross profit of 12.11B and revenue of 15.53B. Therefore, the gross margin over that period was 78.0%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
MRK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Merck & Co., Inc. reported an operating income of 5.94B and revenue of 15.53B, resulting in an operating margin of 38.2%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
MRK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Merck & Co., Inc. reported a net income of 5.08B and revenue of 15.53B, resulting in a net margin of 32.7%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.